Bank of New York Mellon Corp reduced its stake in shares of Casey’s General Stores, Inc. (NASDAQ:CASY – Free Report) by 11.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 418,218 shares of the company’s stock after selling 52,954 shares during the period. Bank of New York Mellon Corp owned about 1.12% of Casey’s General Stores worth $236,427,000 at the end of the most recent quarter. Get Casey' ...

Core Viewpoint - Johnson & Johnson is set to report its fourth-quarter earnings on January 21, with expectations of increased earnings per share and revenue compared to the previous year [1] Financial Performance - Analysts predict fourth-quarter earnings of $2.47 per share, up from $2.04 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $24.16 billion, an increase from $22.52 billion reported last year [1] Recent Developments - On January 14, Johnson & Johnson announced topline results from the Phase 3 MajesTEC-9 study of Tecvayli for multiple myeloma, which may impact investor sentiment [2] - Following the announcement, shares of Johnson & Johnson fell by 0.2% to close at $218.21 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained a Market Perform rating and raised the price target from $193 to $208 [4] - Barclays analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $197 to $217 [4] - Goldman Sachs analyst Asad Haider maintained a Buy rating and raised the price target from $213 to $240 [4] - B of A Securities analyst Tim Anderson maintained a Neutral rating and increased the price target from $204 to $220 [4] - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $190 to $197 [4]

Core Insights - J.B. Hunt Transport Services, Inc. is set to release its fourth-quarter earnings on January 15, with expected earnings of $1.81 per share, an increase from $1.53 per share in the same period last year [1] - The anticipated quarterly revenue for J.B. Hunt is $3.12 billion, slightly down from $3.15 billion a year earlier [1] Dividend and Share Repurchase - On October 22, J.B. Hunt announced a quarterly dividend and a new $1 billion share repurchase authorization [2] - Following this announcement, J.B. Hunt shares experienced a decline of 0.6%, closing at $205.17 [2] Analyst Ratings and Price Targets - Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and raised the price target from $168 to $223 [3] - JP Morgan analyst Brian Ossenbeck maintained an Overweight rating and increased the price target from $176 to $211 [3] - Bernstein analyst David Vernon maintained a Market Perform rating and raised the price target from $158 to $195 [3] - Goldman Sachs analyst Jordan Alliger maintained a Neutral rating and raised the price target from $169 to $187 [3] - Citigroup analyst Ariel Rosa downgraded the stock from Buy to Neutral while raising the price target from $175 to $221 [3]

Core Insights - Franklin Covey Co. is set to release its first-quarter earnings results on January 7, 2025, after market close [1] - Analysts predict earnings of 13 cents per share, a decrease from 20 cents per share in the same quarter last year [1] - The expected quarterly revenue is $64.77 million, down from $69.09 million year-over-year [1] - The company reported mixed results for the fourth quarter on November 5 [1] Stock Performance - Franklin Covey's shares fell by 0.8%, closing at $16.64 on the previous Friday [2] Analyst Ratings - Barrington Research analyst Alexander Paris maintains an Outperform rating with a price target of $22, reflecting an 80% accuracy rate [3] - Roth Capital analyst Jeff Martin has a Buy rating but reduced the price target from $30 to $27, with a 68% accuracy rate [3]

Analyst Upgrades and Downgrades - Goldman Sachs upgraded Teradyne from "sell" to "buy" with a target price increase from $148.00 to $230.00 [1] - UBS raised its price target from $165.00 to $200.00 and maintained a "buy" rating [1] - Bank of America upgraded Teradyne from "underperform" to "buy" with a price objective of $205.00 [1] - Evercore ISI increased its price objective from $120.00 to $175.00 and rated the stock as "outperform" [1] - JPMorgan Chase raised its target price from $122.00 to $190.00 and assigned a "neutral" rating [1] - The consensus rating for Teradyne is "Moderate Buy" with a target price of $185.75 [1] Financial Performance - Teradyne reported $0.85 earnings per share (EPS) for the last quarter, exceeding estimates of $0.78 by $0.07 [3] - The company had revenue of $769.21 million, surpassing analyst estimates of $744.20 million [3] - Quarterly revenue increased by 4.3% year-over-year [3] - The return on equity was 18.04% and the net margin was 15.49% [3] Dividend Announcement - Teradyne announced a quarterly dividend of $0.12 per share, paid on December 17th [4] - The annualized dividend is $0.48, yielding 0.2% [4] - The dividend payout ratio is currently 17.45% [4] Stock Performance - Teradyne's stock reached a new 52-week high of $205.30 during trading [5] - The stock traded at $205.1880 with a volume of 233,326 shares [5] - The company's market capitalization is $32.51 billion, with a P/E ratio of 75.48 [2] Insider Transactions - CEO Gregory Stephen Smith sold 1,108 shares at an average price of $201.31, totaling $223,051.48 [6] - Following the sale, the CEO owns 93,409 shares valued at approximately $18.8 million [6] - Insiders sold 3,324 shares worth $583,639 over the last quarter [6] Institutional Inflows and Outflows - Bank of Nova Scotia increased its holdings in Teradyne by 546.5%, acquiring an additional 83,055 shares [7] - Mirae Asset Global Investments raised its stake by 3.4%, now owning 277,002 shares [7] - Thrivent Financial for Lutherans lifted its position by 291.6%, owning 24,995 shares [7] - Hedge funds and institutional investors own 99.77% of Teradyne's stock [7] Company Overview - Teradyne, Inc. is a global supplier of automatic test equipment and related services for semiconductors and electronic systems [8] - The company was founded in 1960 and is headquartered in North Reading, Massachusetts [8] - Teradyne's product portfolio focuses on automatic test equipment (ATE) and system-level test solutions [9]

Core Viewpoint - Carnival Corporation is expected to report improved earnings and revenue for its fourth quarter, indicating a positive trend in financial performance [1][2]. Financial Performance - The company is projected to report quarterly earnings of 25 cents per share, an increase from 14 cents per share in the same period last year [1]. - The consensus estimate for quarterly revenue is $6.37 billion, compared to $5.94 billion a year earlier [1]. Analyst Ratings - Carnival has exceeded analyst revenue estimates for six consecutive quarters and in nine of the last ten quarters overall [2]. - UBS analyst Robin Farley maintained a Buy rating and raised the price target from $35 to $37 [3]. - Barclays analyst Brandt Montour maintained an Overweight rating and reduced the price target from $37 to $36 [3]. - Susquehanna analyst Christopher Stathoulopoulos maintained a Positive rating and increased the price target from $35 to $40 [3]. - Wells Fargo analyst Trey Bowers maintained an Overweight rating and raised the price target from $34 to $35 [3]. - Citigroup analyst James Hardiman maintained a Buy rating and lowered the price target from $38 to $36 [3].

Group 1 - Top Wall Street analysts have changed their outlook on several major companies, indicating a shift in market sentiment [1] - Analysts have provided insights on CVX stock, suggesting potential investment opportunities [1]

Core Viewpoint - The Lovesac Company is expected to report a significant quarterly loss and a slight increase in revenue compared to the previous year [1] Financial Performance - The company will release its third-quarter earnings results on December 11, with analysts predicting a loss of 46 cents per share, compared to a loss of 1 cent per share in the same quarter last year [1] - The consensus estimate for quarterly revenue is $154.17 million, which represents an increase from last year's revenue of $149.91 million [1] Stock Performance - Shares of Lovesac fell by 1.5%, closing at $13.74 [2] Analyst Ratings - Maxim Group analyst Tim Forte maintains a Buy rating with a reduced price target of $33, down from $38 [3] - DA Davidson analyst Michael Baker also maintains a Buy rating with a price target of $24 [3] - Canaccord Genuity analyst Maria Ripps keeps a Buy rating with a price target of $30 [3] - Oppenheimer analyst Brian Nagel has an Outperform rating with a price target of $35 [3] - Roth MKM analyst Matt Koranda maintains a Buy rating and raised the price target from $22 to $28 [3]

Core Insights - Macy's, Inc. is expected to report a quarterly loss of 13 cents per share for Q3, a decline from a profit of 4 cents per share in the same period last year [1] - The consensus estimate for Macy's quarterly revenue is $4.56 billion, down from $4.74 billion a year earlier [1] - The company's board declared a regular quarterly dividend of 18.24 cents per share on October 24 [1] Stock Performance - Shares of Macy's fell 0.5% to close at $22.71 [2] Analyst Ratings - UBS analyst Jay Sole maintained a Sell rating and raised the price target from $6.5 to $7 [4] - Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and increased the price target from $17 to $22 [4] - Citigroup analyst Paul Lejuez maintained a Neutral rating and raised the price target from $16 to $19 [4] - BTIG analyst Robert Drbul initiated coverage with a Neutral rating [4] - Morgan Stanley analyst Alex Straton maintained an Equal-Weight rating and raised the price target from $12 to $16 [4]

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the year-ago period. The consensus estimate for Pfizer’s quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier, according to Benzinga Pro.On Friday, Pfizer filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk ( ...